(EXEL:Consolidated Issue Listed on NASDAQ Global Select )
Earnings & Estimates Summary - EXELIXIS INC (EXEL)
2013 revenues at Exelixis, Inc. totaled $31.3M USD, while annual losses equaled $1.32 per share.
Quarterly Earnings & Estimates - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Quarterly Earnings
Exelixis, Inc. reported 2nd quarter 2014 losses of $0.37 per share on 08/2/2014.
Annual Earnings & Estimates - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Annual Earnings
Exelixis, Inc. reported annual 2013 losses of $1.32 per share on 02/22/2014.
Quarterly Revenues - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Quarterly Revenues
Exelixis, Inc. had 2nd quarter 2014 revenues of $6.6M USD. This bettered the $6.0M USD consensus of the 6 analysts covering the company. This was -44.7% below the prior year's 2nd quarter results.
Annual Revenues - EXELIXIS INC (EXEL)
Exelixis, Inc.'s Annual Revenues
Exelixis, Inc. had revenues for the full year 2013 of $31.3M USD. This was -34.0% below the prior year's results.
|CTI BioPharma Corp||$1.81 USD||-0.06|
|Curis Inc||$2.40 USD||-0.10|
|Cytokinetics Inc||$6.78 USD||-0.32|
|Evotec AG||€3.75 EUR||-0.07|
|Rigel Pharmaceuticals Inc||$3.57 USD||+0.22|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|